Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.

Livi, Lorenzo; Bonomo, Pierluigi; Meattini, Icro; Simontacchi, Gabriele; Greto, Daniela; Desideri, Isacco; Meacci, Fiammetta; Scotti, Vieri; Cecchini, Sara; Nori, Jacopo; Sanchez, Luis Jose; Orzalesi, Lorenzo; Paiar, Fabiola; Biti, Gianpaolo

Livi, Lorenzo; Bonomo, Pierluigi; Meattini, Icro; Simontacchi, Gabriele; Greto, Daniela; Desideri, Isacco; Meacci, Fiammetta; Scotti, Vieri; Cecchini, Sara; Nori, Jacopo; Sanchez, Luis Jose; Orzalesi, Lorenzo; Paiar, Fabiola; Biti, Gianpaolo.

Affiliation

Livi L; Radiotherapy Unit, IFCA, University of Florence, Via di Barbano 2/A, 50129 Florence, Italy.

Med Oncol ; 30(1): 434, 2013 Mar.

Article in En | MEDLINE | ID: mdl-23283649

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Adult; Aged; Antibodies, Monoclonal, Humanized/administration & dosage; Antibodies, Monoclonal, Humanized/adverse effects; Bevacizumab; Breast Neoplasms/mortality; Breast Neoplasms/pathology; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel/administration & dosage; Paclitaxel/adverse effects; Receptor, ErbB-2; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Med Oncol Journal subject: NEOPLASIAS Year: 2013 Type: Article Affiliation country: Italy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google